April 28 (Reuters) - Teva Pharmaceutical Industries Ltd :
* TEVA PRESENTS NEW LONG-TERM DATA DEMONSTRATING EFFICACY AND SAFETY OF COPAXONE (GLATIRAMER ACETATE INJECTION) 40 MG/ML
* TEVA PHARMACEUTICAL INDUSTRIES LTD - NO NEW OR UNEXPECTED ADVERSE EVENTS EMERGED IN PATIENTS RECEIVING COPAXONE 40 MG/ML FOR UP TO 7 YEARS
* TEVA PHARMACEUTICAL INDUSTRIES LTD - ADVERSE EVENTS WERE GENERALLY MILD AND CONSISTENT WITH WELL-ESTABLISHED SAFETY PROFILE OF COPAXONE Source text for Eikon: Further company coverage:
